Current Report Filing (8-k)
25 May 2023 - 4:06AM
Edgar (US Regulatory)
0001533743
false
0001533743
2023-05-24
2023-05-24
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): May 24, 2023
Commission
file number 001-39531
PROCESSA
PHARMACEUTICALS, INC.
(Exact
name of Registrant as Specified in its Charter)
Delaware |
|
45-1539785 |
(State
or Other Jurisdiction of
Incorporation or Organization) |
|
(I.R.S.
Employer
Identification Number) |
7380
Coca Cola Drive, Suite 106, Hanover, Maryland 21076 |
(Address
of Principal Executive Offices, Including Zip Code) |
(443)
776-3133 |
(Registrant’s
Telephone Number, Including Area Code) |
|
(Former
Name or Former Address, if Changed Since Last Report) |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
symbol(s) |
|
Name
of each exchange on which registered |
Common
stock: Par value $.0001 |
|
PCSA |
|
Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
Emerging
growth company ☐ |
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ |
Item 7.01. Regulation Disclosure.
Dr.
David Young of Processa Pharmaceuticals, Inc. (“Processa”) will participate on a panel at the World Orphan
Drug Congress to be held at the Gaylord National Resort & Convention Center in Washington, DC. The panel, titled, Clinical Development
& Regulatory Panel Session: Patient focused drug development – best practices on patient group and drug developer interaction
with FDA” will be held on May 24, 2023, at 4:20 PM ET. Dr. Young’s presentation will be a Pitch and Partner presentation
titled, “Applying FDA’s Project Optimus to the Next Generation of Chemotherapy Drugs Treating Rare Cancers. This presentation
will be held on May 24th at 1:00 PM in Theater 6.
During
the session, Processa’s presentation will be uploaded into a portal, which is furnished as Exhibit 99.1 and is incorporated herein
by reference. The presentation will also be made available in the “Investors” section on Processa’s website, located
at https://www.processapharmaceuticals.com.
Processa
undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time
to time through the filing of other reports or documents with the Securities Exchange Commission, through press releases, or through
other public disclosure, including in the “Investors” section of Processa’s website. Processa routinely uses its website
as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
The
information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of
the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall they be deemed
incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference
in such filing.
Item
9.01. Financial Statements and Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, hereunto duly authorized, on May 24, 2023.
|
PROCESSA
PHARMACEUTICALS, INC. |
|
Registrant |
|
|
|
|
By: |
/s/
David Young |
|
|
David
Young |
|
|
Chief
Executive Officer |
Processa Pharmaceuticals (NASDAQ:PCSA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Processa Pharmaceuticals (NASDAQ:PCSA)
Historical Stock Chart
From Jul 2023 to Jul 2024